Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been given an average rating of "Buy" by the eleven analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $21.40.
Several research firms recently weighed in on BMEA. Barclays decreased their target price on Biomea Fusion from $11.00 to $3.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 2nd. HC Wainwright reduced their price objective on Biomea Fusion from $40.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. D. Boral Capital reiterated a "buy" rating and issued a $16.00 price objective on shares of Biomea Fusion in a research note on Tuesday, June 24th. Oppenheimer set a $10.00 price objective on Biomea Fusion in a research note on Monday, March 24th. Finally, Piper Sandler began coverage on Biomea Fusion in a research note on Tuesday, June 3rd. They issued an "overweight" rating and a $7.00 price objective for the company.
Get Our Latest Stock Report on BMEA
Biomea Fusion Trading Up 0.2%
BMEA stock traded up $0.00 during trading on Friday, hitting $1.65. 1,289,449 shares of the company's stock were exchanged, compared to its average volume of 1,159,386. The business has a 50-day moving average price of $1.91 and a two-hundred day moving average price of $2.72. The stock has a market capitalization of $62.14 million, a price-to-earnings ratio of -0.47 and a beta of -0.13. Biomea Fusion has a 52-week low of $1.29 and a 52-week high of $13.07.
Biomea Fusion (NASDAQ:BMEA - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.04. On average, equities research analysts anticipate that Biomea Fusion will post -3.93 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. increased its holdings in shares of Biomea Fusion by 14.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 24,005 shares of the company's stock valued at $93,000 after purchasing an additional 3,005 shares during the period. Wexford Capital LP increased its holdings in shares of Biomea Fusion by 2.3% in the fourth quarter. Wexford Capital LP now owns 133,343 shares of the company's stock valued at $517,000 after purchasing an additional 3,007 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Biomea Fusion by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 12,914 shares of the company's stock valued at $50,000 after purchasing an additional 4,399 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Biomea Fusion by 27.6% in the fourth quarter. JPMorgan Chase & Co. now owns 22,535 shares of the company's stock valued at $87,000 after purchasing an additional 4,868 shares during the period. Finally, Barclays PLC increased its holdings in shares of Biomea Fusion by 18.4% in the fourth quarter. Barclays PLC now owns 46,904 shares of the company's stock valued at $182,000 after purchasing an additional 7,284 shares during the period. Institutional investors and hedge funds own 96.72% of the company's stock.
About Biomea Fusion
(
Get Free ReportBiomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.
See Also

Before you consider Biomea Fusion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biomea Fusion wasn't on the list.
While Biomea Fusion currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.